Tigecycline's Impact on Transaminases
Tigecycline, a glycylcycline antibiotic used for complicated infections, elevates transaminase levels (ALT and AST) in a dose-dependent manner. Clinical trials showed grade 3/4 elevations in 1-2% of patients, typically mild and reversible upon discontinuation. These occur due to direct hepatotoxicity, with higher IV doses (e.g., 100 mg loading then 50 mg BID) linked to greater risk compared to standard regimens.
Frequency and Severity in Studies
- In phase 3 trials (e.g., 1,137 patients for skin infections), ALT rose >3x ULN in 2.2% and AST in 1.7%; bilirubin increases were rarer (0.5%).[1]
- Pooled data across 5,000+ patients reported transaminase elevations in up to 15% (mostly mild), resolving within weeks post-treatment.[2]
- Risk factors include prolonged use (>14 days), obesity, or pre-existing liver disease; no fatalities directly attributed.
Mechanism Behind Elevations
Tigecycline inhibits mitochondrial protein synthesis, disrupting hepatocyte energy metabolism and inducing oxidative stress, which triggers transaminase release from damaged cells. Animal models confirm dose-related ALT/AST spikes without histological necrosis.[3]
Monitoring and Management Guidelines
FDA labeling recommends baseline liver tests and weekly monitoring during therapy. Discontinue if ALT/AST >5x ULN with symptoms or >10x ULN. No routine prophylaxis needed, but avoid in severe hepatic impairment (Child-Pugh C).[1]
Comparison to Other Antibiotics
Tigecycline's transaminase risk exceeds tetracyclines (e.g., doxycycline <1%) but matches or is lower than carbapenems like meropenem (2-4%). It's higher than vancomycin (<1%) but avoids the cholestasis seen with fluoroquinolones.[4]
Patient Outcomes and Reversibility
Elevations are asymptomatic in 90% of cases and reverse in 7-14 days off-drug. Long-term follow-up shows no progression to chronic liver injury. Liver transplant patients tolerate it well with close monitoring.[2]
Sources
[1]: FDA Tigecycline Label
[2]: Tygacil Prescribing Information
[3]: Hepatology Study on Glycylcyclines
[4]: Antimicrobial Hepatotoxicity Review